How does HBV interact with the immune system?

Size: px
Start display at page:

Download "How does HBV interact with the immune system?"

Transcription

1 How does HBV interact with the immune system? International Workshop on HBV Cure Toronto 2017 Mala Maini Division of Infection and Immunity UCL

2 Disclosures Mala Maini: collaborative research funding from Gilead Sciences, Roche and Immunocore advisory boards and /or consultant for Gilead Sciences, Roche, Arbutus Biopharma

3 CD8 T cell depletion and dysfunction in persistent HBV? Acute resolving HBV Chronic HBV CD8 T cells Granzyme Perforin INF-g TNF-a IL-2 Infected hepatocytes Effective T cells control virus Infected hepatocytes Exhausted T cells loose control of virus

4 Restoration of endogenous T cells for functional cure Acute resolving HBV Chronic HBV CD8 T cells Granzyme Perforin INF-g TNF-a IL-2 Infected hepatocytes Effective T cells control virus Infected hepatocytes Exhausted T cells loose control of virus Feasible? Safe? How? In whom? Reviewed in Maini and Pallett, Lancet Gastro Hep in press

5 High antigen load and the liver environment drive T cell exhaustion in HBV Persistent high antigen load Infected hepatocytes + Defective particles fold excess over virions Tolerogenic liver environment Hepatocyte Blood from portal vein MAIT B cell CD4 NK CD8 T reg Space of Disse LSEC MDSC Kupffer cell Stellate cell

6 Multiple immune defects in HBV infection B cells skewed: IL-10-mediated T cell suppression Das JI 2012 B cell MAIT CD4 NK CD8 T reg Space of Disse MDSC Hepatocyte LSEC Kupffer cell Classical memory B cells replaced with atypicals Stellate cell Burton unpublished

7 Multiple immune defects in HBV infection Hepatocyte MAIT NK T reg Space of Disse LSEC MDSC Kupffer cell CD4 CD8 Stellate cell NK cells have defective IFN-g production Oliviero Gastro 2009 Bonorino J Hep 2009 Peppa PLoS Path 2010 Tjwa J Hep 2011

8 HBV hijacks the tolerogenic liver landscape Hepatocyte NK T reg Space of Disse LSEC Rapid, contact-dependent NK cell killing of HBV-specific T cells Kupffer cell CD4 CD8 Peppa JEM 2013 Boni Hepatol 2015 Huang JI 2017 Stellate cell Liver-resident NK cells have inducible TRAIL Stegmann et al, Sci Rep 2016 HBV-specific T cells upregulate TRAIL-R2 rendering them susceptible to NK cell-mediated deletion

9 HBV hijacks the tolerogenic liver landscape HBV-specific T cells are exhausted and pro-apoptotic Hepatocyte MAIT NK T reg Space of Disse LSEC MDSC Kupffer cell B cell CD4 CD8 Stellate cell Intrahepatic priming predisposes to Bim-mediated apoptosis Lopes et al JCI 2008 Ongoing exposure to co-inhibitory receptors and immunoregulatory cytokines drives exhaustion Dunn et al Gastroenterology 2009, Schurich et al Hepatology 2011, Das et al JI 2012 Nebbia et al PLoS One 2012, Schurich et al PLoS Path 2013

10 IL-12 synergises PD-1 rescue and overcomes mitochondrial defects

11 Going deeper than Checkpoint inhibitors: Targeting mitochondrial dysfunction Reversal of defects with mitochondrial antioxidants Mito-Q and MitoTempo

12 Metabolic checkpoints in HBV infection HBV-specific T cells are exhausted and pro-apoptotic Hepatocyte MAIT NK T reg Space of Disse LSEC MDSC Kupffer cell CD4 CD8 NK cells have defective IFN-g production NK cells delete HBV-specific T cells Stellate cell MDSC inhibit T cells through nutrient deprivation Das JEM 2008 Pallett Nat Med 2015

13 Expanded arginase+ myeloid-derived suppressor cells deprive T cells of arginine Hepatocyte Laura Pallett CD4 NK CD8 T reg Space of Disse LSEC MDSC Kupffer cell MDSC inhibit T cells through nutrient deprivation Stellate cell gmdsc

14 gmdsc (% of myeloid) Arginase I MFI ( 10 3 ) CD63 MFI Degranulating arginase+ gmdsc accumulate in the liver Hepatocyte Circulation NK T reg Space of Disse MDSC LSEC Kupffer cell CD4 CD8 Stellate cell Liver gmdsc: 60 Frequency Arginase Degranulation *** 30 ** 4,000 ** ,000 2, ,000 0 PBMC IHL 0 PBMC IHL 0 PBMC IHL

15 Metabolic regulation of T cells in viral hepatitis gmdsc arginase1 depletes extracellular arginine Pallett et al, Nat Med 2015 T cell arginase2 depletes intracellular arginine Geiger et al, Cell 2016 Arginine starvation of T cells: Impairs T cell proliferation, survival & antiviral function?drives mitochondrial defects

16 Boosting immunity in HBV: will it be safe? The trade-off between immunity and immunopathology HBV is a non-cytopathic virus Resultant liver disease is immune-mediated Immune responses e.g. CD8 T cells can mediate protection and liver injury Hepatic flares an inevitable result of effective immune boosting? Minimise antigen load need studies on extent of infected hepatocytes Select patients with good liver reserve Focus T cell boosting on HBV-specific component Develop adjunctive approaches to limit collateral damage

17 Which patients should be targeted for HBV functional cure? No consensus May vary depending on therapeutic strategy Suppressed on antivirals +/- prior HBeAg seronconversion Low level carriers Consider early in course of disease/younger patients -early HBV integration -major pool of infection -subtle liver damage -immune system less exhausted : Experimental immunotherapies can be tested first in HBV-related HCC e.g. Nivolumab

18 Tissue-resident T cells: front-line sentinels Laura Pallett Circulation Liver

19 CD103 % CD69 + CD103 + CD8+ T cells (as % of CD8+) CD8 T cells expressing tissue-retention signals sequestered in healthy human liver Blood Liver Healthy liver CRC margin Perfusate **** **** **** CD69 + CD103 + tissue-resident population CD69 0 Blood Liver 16 colour flow cytometry of 54 fresh liver samples Transcriptionally distinct: T-bet lo Eomes lo Blimp-1 hi Hobit lo Pallett et al J Exp Med 2017

20 (% CD45RA - ) (% CD45RA - ) (% CD45RA - ) Expansion of liver-resident CD8 T cell compartment in HBV immune controllers 60 **** 80 **** % CD69 + CD103 + T RM Blood Liver HBV % CD69 + CD103 + T RM Control HBV % CD69 + CD103 + T RM **** ** * 0 2x10 3 2x10 3-2x10 5 Viral load (IU/ml) 2x10 5 healthy

21 Multispecific HBV-specific T cells compartmentalised in the liver following HBV resolution Resolved HBV: sag-, anti-hbc+ Only reactivate upon immune suppression Gold-standard immune response to HBV Liver immunity never previously studied in this setting Overnight peptide stimulation of liver perfusate from HBV resolved donor:

22 Tissue-resident T cells in the human liver: Poised for frontline defence Hepatocyte NK T reg Space of Disse LSEC Kupffer cell CD4 CD8 Stellate cell Define signature of tissue-resident CD8 T cells in human liver --cannot be sampled in periphery -expand in HBV especially in those with good viral control -features that instruct their retention, survival, rapid non-cytolytic antiviral function -signals capable of recapitulating their induction Aim for induction of tissue-resident memory cells for functional cure Need for liver sampling in functional cure studies

23 Ross Lopes Abhishek Das Claire Dunn Pooja Khanna Lorenzo Micco Gaia Nebbia Wei-Chen Huang Simran Singh Itziar Otano Kasha Singh Dimitra Peppa Emily Colbeck UCL collaborators Niclas Thomas Nathan Davies Victoria Male Guiseppe Fusai Eleni Nastouli Richard Gilson Amir Gander Brian Davidson Francis Robertson William Rosenberg Tu Vinh Luong Acknowledgements Division of Infection and Immunity, UCL Barts & the London Hospital Upkar Gill Jyoti Hansi Patrick Kennedy All healthy donors, patients and clinic staff Laura Pallett Kerstin Stegmann Anna Schurich Jessica Davies Nicholas Easom Alice Burton Nathalie Schmidt Leo Swadling Mariana Diniz Kornelija Suveizdyte Oliver Amin University of Dundee Linda Sinclair Doreen Cantrell A*Star, Singapore Antonio Bertoletti

Checkpoint inhibitors for HBV cure

Checkpoint inhibitors for HBV cure Checkpoint inhibitors for HBV cure Mala Maini Division of Infection and Immunity UCL, London Toronto HBV Cure 2016 Reversal of T cell exhaustion: the goal of checkpoint inhibitors CD8 T cells Granzyme

More information

CHRONIC HEPATITIS B VIRUS Prospects for Cure

CHRONIC HEPATITIS B VIRUS Prospects for Cure VIRAL HEPATITIS and CO-INFECTION with HIV Bucharest, Romania, 6-7 October, 2016 CHRONIC HEPATITIS B VIRUS Prospects for Cure Patrick T. F. Kennedy Reader in Hepatology & Consultant Hepatologist Blizard

More information

Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D.

Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D. Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D. Biology Lead Toronto Centre for Liver Disease Toronto General Hospital Research Institute University Health Network (UHN) HBV

More information

Will Antigen Depletion Restore HBVspecific

Will Antigen Depletion Restore HBVspecific Will Antigen Depletion Restore HBVspecific Immunity? Adam J. Gehring, Ph.D. Biology Lead Toronto Centre for Liver Disease University Health Network (UHN) Assistant Professor Department of Immunology University

More information

C. Ferrari Unit of Infectious Diseases and Hepatology Laboratory of Viral Immunopathology Azienda Ospedaliero-Universitaria di Parma Italy

C. Ferrari Unit of Infectious Diseases and Hepatology Laboratory of Viral Immunopathology Azienda Ospedaliero-Universitaria di Parma Italy HBV and the immune response C. Ferrari Unit of Infectious Diseases and Hepatology Laboratory of Viral Immunopathology Azienda Ospedaliero-Universitaria di Parma Italy List of topics - Kinetics of immune

More information

HBV and the immune response

HBV and the immune response HBV and the immune response C. Ferrari Unit of Infectious Diseases and Hepatology Laboratory of Viral Immunopathology Azienda Ospedaliero-Universitaria di Parma Italy List of topics - Kinetics of immune

More information

New insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre

New insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures

More information

Are Immune Modulators Really Needed to Cure HBV infection?

Are Immune Modulators Really Needed to Cure HBV infection? Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,

More information

Why do we need new HBV treatment and what is our definition for cure?

Why do we need new HBV treatment and what is our definition for cure? Why do we need new HBV treatment and what is our definition for cure? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University

More information

Hepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review

Hepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review Hepatitis virus immunity Mar 9, 2005 Rehermann and Nascimbeni review Crispe review HBV & HCV infection outcomes Both viruses cause immune-mediated active and chronic hepatitis HBV Vertical transmission

More information

Darwinian selection and Newtonian physics wrapped up in systems biology

Darwinian selection and Newtonian physics wrapped up in systems biology Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

Persistent infection with hepatitis B virus (HBV)

Persistent infection with hepatitis B virus (HBV) Role of the Coinhibitory Receptor Cytotoxic T Lymphocyte Antigen-4 on Apoptosis-Prone CD8 T Cells in Persistent Hepatitis B Virus Infection Anna Schurich, 1 * Pooja Khanna, 1,2 * A. Ross Lopes, 1 Ki Jun

More information

HBV Novel Therapies Maria Buti MD, PhD

HBV Novel Therapies Maria Buti MD, PhD HBV Novel Therapies Maria Buti MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital CONFLICT OF INTEREST I have financial relationships to disclose within the past 12 months relevant

More information

Tim-3 as a target for tumor immunotherapy

Tim-3 as a target for tumor immunotherapy Tim-3 as a target for tumor immunotherapy Ana Carrizosa Anderson Brigham and Women s Hospital Harvard Medical School Disclosures A portion of the work has been performed as part of a sponsored research

More information

Synergistic combinations of targeted immunotherapy to combat cancer

Synergistic combinations of targeted immunotherapy to combat cancer Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic

More information

Tumor Microenvironment and Immune Suppression

Tumor Microenvironment and Immune Suppression Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation

More information

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement

Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Hepatitis B Cure: from discovery to regulatory endpoints in HBV clinical research A summary of the AASLD/EASL statement Fabien Zoulim Service d hépatologie, Hospices Civils de Lyon INSERM U1052, Cancer

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

Micro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier

Micro 204. Cytotoxic T Lymphocytes (CTL) Lewis Lanier Micro 204 Cytotoxic T Lymphocytes (CTL) Lewis Lanier Lewis.Lanier@ucsf.edu Lymphocyte-mediated Cytotoxicity CD8 + αβ-tcr + T cells CD4 + αβ-tcr + T cells γδ-tcr + T cells Natural Killer cells CD8 + αβ-tcr

More information

Oncolytic Virotherapy: Targeting Cancer Stem Cells

Oncolytic Virotherapy: Targeting Cancer Stem Cells Oncolytic Virotherapy: Targeting Cancer Stem Cells Cancer Stem Cells (CSCs) or Cancer Initiating Cells (CICs) A consensus of five defining criteria has been established to affirm the existence of CICs:

More information

Infection of parenchymal organs with noncytopathic. Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells

Infection of parenchymal organs with noncytopathic. Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells GASTROENTEROLOGY 2012;143:78 87 Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells ELENA SANDALOVA,* DILETTA LACCABUE, CAROLINA BONI, TSUNAMASA WATANABE, ANTHONY

More information

Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen

Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?

More information

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research

More information

Hepatitis B New Therapies

Hepatitis B New Therapies Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth

More information

Therapeutic immunization strategies in chronic hepatitis B

Therapeutic immunization strategies in chronic hepatitis B Therapeutic immunization strategies in chronic hepatitis B Mengji Lu Institut für Virologie Universitätsklinkum Essen Falk Symposium Berlin, 04. October 2005 The aim of therapeutic immunization to achieve

More information

Hepatitis B and D Update on clinical aspects

Hepatitis B and D Update on clinical aspects Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy

More information

Special situations: Patients with liver metastasis or liver primary tumor. Erika Martinelli, MD PhD Medical Oncologist

Special situations: Patients with liver metastasis or liver primary tumor. Erika Martinelli, MD PhD Medical Oncologist Special situations: Patients with liver metastasis or liver primary tumor Erika Martinelli, MD PhD Medical Oncologist Outline: Liver (anatomy, basic functions) Liver Immuno-landscape Immuno-landscape in

More information

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?

More information

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation

More information

Apoptosis in chronic hepatitis C

Apoptosis in chronic hepatitis C Apoptosis in chronic hepatitis C Dr med. Anna Parfieniuk-Kowerda Department of Infectious Diseases and Hepatology Medical University of Bialystok Poland APOPTOSIS Apoptosis - type I programmed cell death

More information

Induction and Clearance of Latent HIV Infection:

Induction and Clearance of Latent HIV Infection: 214 Towards an HIV Cure symposium Melbourne Induction and Clearance of Latent HIV Infection: an Ex-Vivo Assessment of Immune Effectors using Cells from ART-treated Patients DM Margolis 1, C Garrido 1,

More information

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University

Hepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph

More information

Natural History of Chronic Hepatitis B

Natural History of Chronic Hepatitis B Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.

More information

Immunotherapy for Chronic Hepatitis B Virus Infection

Immunotherapy for Chronic Hepatitis B Virus Infection Gut and Liver, Vol. 12, No. 5, September 2018, pp. 497-507 Review Immunotherapy for Chronic Hepatitis B Virus Infection Antonio Bertoletti 1,2 and Nina Le Bert 1,2 1 Emerging Infectious Diseases Program,

More information

Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection

Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection Blockade of Immunosuppressive Cytokines Restores NK Cell Antiviral Function in Chronic Hepatitis B Virus Infection Peppa, D; Micco, L; Javaid, A; Kennedy, PTF; Schurich, A; Dunn, C; Pallant, C; Ellis,

More information

4th International HIV/Viral Hepatitis Co-Infection Meeting

4th International HIV/Viral Hepatitis Co-Infection Meeting 4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings

More information

Are booster immunisations needed for lifelong hepatitis B immunity?

Are booster immunisations needed for lifelong hepatitis B immunity? Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support

More information

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared

More information

Natural Killer Cells Are Characterized by the Concomitantly Increased Interferon-c and Cytotoxicity in Acute Resolved Hepatitis B Patients

Natural Killer Cells Are Characterized by the Concomitantly Increased Interferon-c and Cytotoxicity in Acute Resolved Hepatitis B Patients Natural Killer Cells Are Characterized by the Concomitantly Increased Interferon-c and Cytotoxicity in Acute Resolved Hepatitis B Patients Juanjuan Zhao 1., Yonggang Li 2., Lei Jin 3, Shuye Zhang 3, Rong

More information

Alcoholic hepatitis is a drug-induced disorder

Alcoholic hepatitis is a drug-induced disorder Alcoholic hepatitis is a drug-induced disorder Gyongyi Szabo, MD, PhD Professor of Medicine University of Massachusetts Medical School Source: 2 Sobernation.com Clinical Progression of ALD Mortality Acute

More information

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical

More information

Short Duration DAA Therapy for Hepatitis C: How Short Can We Go?

Short Duration DAA Therapy for Hepatitis C: How Short Can We Go? Short Duration DAA Therapy for Hepatitis C: How Short Can We Go? Shyam Kottilil MD, Ph.D. Institute of Human Virology, University of Maryland, Baltimore, MD HEPDART Kona, HI Disclosures Received research

More information

Anti-HBc: state of the art what is the CORE of the issues?

Anti-HBc: state of the art what is the CORE of the issues? Anti-HBc: state of the art what is the CORE of the issues? Robert G Gish MD Adjunct Professor Stanford University Medical Director Hepatitis B Foundation Disclosures: See robertgish.com If you wish an

More information

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction

More information

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr

More information

Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy

Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma

More information

Acute Hepatitis B Virus Infection with Recovery

Acute Hepatitis B Virus Infection with Recovery Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis

More information

Don t interfere My first choice is always nucs!

Don t interfere My first choice is always nucs! Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr

More information

SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca

SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP 2139-Ca Louis Jansen 1,2, Andrew Vaillant 3, Karel van Dort 1, Femke Stelma 1,2, Neeltje

More information

La riattivazione dell epatite virale nel paziente in terapia biologica

La riattivazione dell epatite virale nel paziente in terapia biologica La riattivazione dell epatite virale nel paziente in terapia biologica Claudio Puoti S.C. di Medicina Interna e Medicina Epato-Gastroenterologica Osp. di Marino-Frascati - Roma Patterns of HBV-related

More information

Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees

Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees Robert Lanford 1, Bernadette Guerra 1, Deborah Chavez 1, Vida L. Hodara 1, Xubin Zheng 2, Grushenka Wolfgang 3, Daniel B.

More information

CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways

CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways Laura Strauss, Christoph Bergmann, Theresa L. Whiteside University

More information

Hepatitis delta: often forgotten?

Hepatitis delta: often forgotten? 15 th Annual Resistance and Antiviral Therapy Meeting Dr Sarah Hughes King s College Hospital, London Thursday 29 September 2011, Royal College of Physicians, London Hepatitis delta: often forgotten? Dr

More information

HD1 (FLU) HD2 (EBV) HD2 (FLU)

HD1 (FLU) HD2 (EBV) HD2 (FLU) ramer staining + anti-pe beads ramer staining a HD1 (FLU) HD2 (EBV) HD2 (FLU).73.11.56.46.24 1.12 b CD127 + c CD127 + d CD127 - e CD127 - PD1 - PD1 + PD1 + PD1-1 1 1 1 %CD127 + PD1-8 6 4 2 + anti-pe %CD127

More information

HBV Cure Definition and New Drugs in Development

HBV Cure Definition and New Drugs in Development HBV Cure Definition and New Drugs in Development Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada

More information

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer

More information

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017

More information

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune

More information

Hepatitis B: An Update COPYRIGHT

Hepatitis B: An Update COPYRIGHT Hepatitis B: An Update Sanjiv Chopra, M.D. Professor of Medicine Harvard Medical School James Tullis Firm Chief Department of Medicine Beth Israel Deaconess Medical Center A Tale of Serendipity Baruch

More information

Supplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs

Supplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs Supplementary Table Clinicopathological characteristics of 35 patients with CRCs Characteristics Type-A CRC Type-B CRC P value Sex Male / Female 9 / / 8.5 Age (years) Median (range) 6. (9 86) 6.5 (9 76).95

More information

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural

More information

CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION

CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION Justin Kline 1, Long Zhang 1, and Thomas F. Gajewski 1,2 Departments

More information

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop

More information

Hepatitis B Virus infection: virology

Hepatitis B Virus infection: virology Hepatitis B Virus infection: virology 167 Falk Symposium: Liver under constant attack from fat to viruses III Falk Gastro-Konferenz 17.-21. September 2008 Congress Centrum Mainz Maura Dandri Department

More information

Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic

Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic isbtc 10-13 November 2005 Valeria Milani, MD, PhD Munich Agenda 1. NK ligands

More information

An HCV Vaccine: Can we get there?

An HCV Vaccine: Can we get there? An HCV Vaccine: Can we get there? Andrea L. Cox, MD,PhD Viral Hepatitis Center No Conflicts of Interest Outline Reasons to develop an HCV vaccine What constitutes protective immunity to HCV What challenges

More information

Immunology CANCER IMMUNOLOGY

Immunology CANCER IMMUNOLOGY Immunology د. عائدة الدرزي Lec. 6 CANCER IMMUNOLOGY Oncogenesis (passes through two stages): 1- Reversible change Normal transformed cells 2- Irreversible change Transformed oncogenic cells Factors causing

More information

Modeling Kinetics of HBV Infection and Recommendations for Moving Forward

Modeling Kinetics of HBV Infection and Recommendations for Moving Forward Modeling Kinetics of HBV Infection and Recommendations for Moving Forward Alan S. Perelson Theoretical Biology and Biophysics Los Alamos National Laboratory Los Alamos, NM HBV Models Hepatology 1999 Tsiang

More information

HEPATITIS B: WHO AND WHEN TO TREAT?

HEPATITIS B: WHO AND WHEN TO TREAT? HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of

More information

Effects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB)

Effects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB) Effects of (SB9200) Therapy on Immune Responses Patients with Chronic Hepatitis B (CHB) Renae Walsh 1, Rachel Hammond 1, Kathy Jackson 1, Ros Edwards 1, Chelsea Macfarlane 2, Radhakrishnan P. Iyer 2, Man

More information

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL

Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the

More information

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.

More information

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,

More information

Immunobiology of hepatitis B virus infection

Immunobiology of hepatitis B virus infection bs_bs_banner doi: 10.1111/hepr.12439 Review Article Immunobiology of hepatitis B virus infection Masanori Isogawa and Yasuhito Tanaka Department of Virology and Liver Unit, Nagoya City University Graduate

More information

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document. Reply to: To target or not to target viral antigens in HBV related HCC? by Buschow et al Qasim, Waseem; Brunetto, Maurizia; Gehring, Adam; Maini, Mala; Bonino, Ferruccio; Stauss, Hans; Bertoletti, Antonio

More information

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology

Basics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers

More information

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013 Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope

More information

Hepatitis B Diagnosis and Management. Marion Peters University of California San Francisco

Hepatitis B Diagnosis and Management. Marion Peters University of California San Francisco Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage

More information

Biology of Immune Aging

Biology of Immune Aging Biology of Immune Aging Jorg J. Goronzy Stanford University Immune deficiency Increase morbidity and mortality from infections Poor vaccine responses Cancer Immune Aging Chronic inflammation Coronary artery

More information

Immune response. This overview figure summarizes simply how our body responds to foreign molecules that enter to it.

Immune response. This overview figure summarizes simply how our body responds to foreign molecules that enter to it. Immune response This overview figure summarizes simply how our body responds to foreign molecules that enter to it. It s highly recommended to watch Dr Najeeb s lecture that s titled T Helper cells and

More information

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer

More information

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a

Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,

More information

Disclosures. Pathogenesis of Autoimmunity Normal immune response: 11/5/2011. Methotrexate and JUN Pathway Activation in Rheumatoid Arthritis

Disclosures. Pathogenesis of Autoimmunity Normal immune response: 11/5/2011. Methotrexate and JUN Pathway Activation in Rheumatoid Arthritis Methotrexate and JUN Pathway Activation in Rheumatoid Arthritis Disclosures N. Olsen and T. Aune are co-founders of ArthroChip LLC. Nancy J. Olsen Penn State MS Hershey Medical Center Thomas M. Aune Vanderbilt

More information

Diseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc.

Diseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc. Diseases of Immunity 2017 CL Davis General Pathology Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc. Autoimmunity Reflects a loss of immunologic tolerance Mechanisms Auto-antibodies

More information

Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4

Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4 Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4 Ankita Garg, Rodney Trout and Stephen A. Spector,,* Department

More information

HLA-E restricted responses in Tuberculosis

HLA-E restricted responses in Tuberculosis HLA-E restricted responses in Tuberculosis Simone A. Joosten Dept. of Infectious Diseases LEIDEN UNIVERSITY MEDICAL CENTER Unconventional immunity Conventional immunity: T cells reactive to complexes of

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

Distinct Metabolic Requirements of Exhausted and Functional Virus- Specific CD8 T Cells in the Same Host.

Distinct Metabolic Requirements of Exhausted and Functional Virus- Specific CD8 T Cells in the Same Host. Distinct Metabolic Requirements of Exhausted and Functional Virus- Specific CD8 T Cells in the Same Host. Schurich, A; Pallett, LJ; Jajbhay, D; Wijngaarden, J; Otano, I; Gill, US; Hansi, N; Kennedy, PT;

More information

Hepatitis C Virus and Cytokine Responses

Hepatitis C Virus and Cytokine Responses Hepatitis C Virus and Cytokine Responses Eui-Cheol Shin, M.D., Ph.D. Laboratory of Immunology & Infectious Diseases (LIID), Graduate School of Medical Science & Engineering (GSMSE), KAIST Daejeon, Korea

More information

HBV Cure Overview of Viral and Immune Targets

HBV Cure Overview of Viral and Immune Targets HBV Cure Overview of Viral and Immune Targets Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada October

More information

Cornerstones of Hepatitis B: Past, Present and Future

Cornerstones of Hepatitis B: Past, Present and Future Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related

More information

6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami

6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami Grant/Research Support: AbbVie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen, Discovery Life Sciences, Beckman Coulter, Inc., Siemens Corporation, MedMira Inc., Conatus Eugene R.

More information

Cell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC)

Cell Mediated Immunity CELL MEDIATED IMMUNITY. Basic Elements of Cell Mediated Immunity (CMI) Antibody-dependent cell-mediated cytotoxicity (ADCC) Chapter 16 CELL MEDIATED IMMUNITY Cell Mediated Immunity Also known as Cellular Immunity or CMI The effector phase T cells Specificity for immune recognition reactions TH provide cytokines CTLs do the

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver

More information

Bible Class: Hepatitis B Virus Infection

Bible Class: Hepatitis B Virus Infection Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:

More information

26/09/2014. Chronic HBV Infection (n = >370 million world-wide n = 218,000 in Australia) HBV REACTIVATION

26/09/2014. Chronic HBV Infection (n = >370 million world-wide n = 218,000 in Australia) HBV REACTIVATION Chronic HBV (n = >37 million world-wide n = 218, in Australia) HBV REACTIVATION PLAYING WITH FIRE Maggie Bassendine 5-3 Yrs HBV (up to 2 billion people world-wide, up to 2 million in Australia) 5-3 Yrs

More information

Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to

Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to Class II tetramer staining Commercially available HLA Class II tetramers (Beckman Coulter) conjugated to PE were combined with dominant HIV epitopes (DRB1*0101-DRFYKTLRAEQASQEV, DRB1*0301- PEKEVLVWKFDSRLAFHH,

More information

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar

Choice of Oral Drug for Hepatitis B: Status Asokananda Konar Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite

More information